Dermapharm 

$47.69
65
+$0.00+0% Tuesday 13:44

Statistics

Day High
47.69
Day Low
47.69
52W High
53
52W Low
39.56
Volume
200
Avg. Volume
1
Mkt Cap
0
P/E Ratio
17.38
Dividend Yield
2.1%
Dividend
1

Upcoming

Dividends

2.1%Dividend Yield
Jul 26
$1.00
Jul 25
$1.06
Jul 25
$1.06
Jul 24
$0.94
Jun 23
$1.15
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

12NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
0.39
0.59
0.78
0.97
Expected EPS
N/A
Actual EPS
N/A

Financials

11.37%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
1.34BRevenue
152.44MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow DMPHF. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Novartis
NVS
Mkt Cap292.35B
Novartis is a global healthcare company that operates in the pharmaceuticals sector, competing with Dermapharm in various therapeutic areas.
Pfizer
PFE
Mkt Cap159.36B
Pfizer is a large pharmaceutical company with a wide range of products that compete with Dermapharm's offerings in the healthcare market.
Merck
MRK
Mkt Cap366B
Merck & Co., Inc. is a leading pharmaceutical company that develops medicines, vaccines, biologic therapies, and animal health products, competing with Dermapharm in several areas.
GSK
GSK
Mkt Cap101.78B
GlaxoSmithKline is a global healthcare company that produces pharmaceuticals and vaccines, directly competing with Dermapharm in the healthcare and pharmaceutical sectors.
Johnson & Johnson
JNJ
Mkt Cap645.95B
Johnson & Johnson is a diversified healthcare company that produces pharmaceuticals, medical devices, and consumer health products, competing with Dermapharm across multiple segments.
Sanofi
SNY
Mkt Cap107.39B
Sanofi is a global biopharmaceutical company focused on human health, directly competing with Dermapharm in the pharmaceutical and healthcare sectors.
Abbvie
ABBV
Mkt Cap451.46B
AbbVie is a biopharmaceutical company that develops and markets therapies focused on treating serious medical conditions, competing with Dermapharm in the healthcare sector.
Roche
RHHBY
Mkt Cap334.28B
Roche Holding AG is a healthcare company that operates in pharmaceuticals and diagnostics, competing with Dermapharm in the development and marketing of pharmaceutical products.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap42.46B
Teva Pharmaceutical Industries Ltd. is a global leader in generic and specialty medicines, competing with Dermapharm in the generic pharmaceuticals market.

About

Dermapharm Holding SE is an international pharmaceutical company specializing in off-patent branded medications, serving both domestic and global markets. Its business is structured across three distinct segments: Branded Pharmaceuticals and Other Healthcare Products, Parallel Imports, and Herbal Extracts. The company's comprehensive activities encompass the development, production, licensing, marketing, and distribution of its offerings. Its product range includes reputable generic drugs, non-prescription remedies, natural over-the-counter treatments, and a variety of other health products. These target diverse medical fields, such as vitamin and mineral supplementation, nutritional support, skin conditions (dermatology), allergies, pain relief, cardiovascular health, women's health (gynecology), and urological issues. Key brands in its portfolio feature Dekristol, Dekristolvit, Allergovit, and Tromcardin. Additionally, Dermapharm provides medical devices like bite away and Herpotherm, alongside specific treatments such as the Momekort nasal spray for allergy symptoms and Azedil, available as a nasal spray or eye drops. Within its Parallel Imports division, Dermapharm brings original pharmaceuticals to market under the axicorp brand. The Herbal Extracts segment supplies natural active ingredients and botanical extracts primarily for phytopharmaceuticals, nutraceuticals, and cosmetic applications. The company's distribution network reaches pharmaceutical wholesalers, individual pharmacies, hospitals, and health food stores. Founded in 1991 and headquartered in Grünwald, Germany, Dermapharm Holding SE operates as a subsidiary of Themis Beteiligungs-Aktiengesellschaft.
Show more...
CEO
Hans-Georg Feldmeier
Employees
3500
Country
Germany
ISIN
DE000A2GS5D8
WKN
000A2GS5D

Listings

0 Comments

Share your thoughts

FAQ

What is Dermapharm stock price today?
The current price of DMPHF is $47.69 USD — it has increased by +0% in the past 24 hours. Watch Dermapharm stock price performance more closely on the chart.
What is Dermapharm stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Dermapharm stocks are traded under the ticker DMPHF.
Is Dermapharm stock price growing?
DMPHF stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Dermapharm has showed a +20.55% increase.
When is the next Dermapharm earnings date?
Dermapharm is going to release the next earnings report on November 12, 2026.
What were Dermapharm earnings last quarter?
DMPHF earnings for the last quarter are 0.54 USD per share, whereas the estimation was N/A USD resulting in a N/A surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Dermapharm revenue for the last year?
Dermapharm revenue for the last year amounts to 1.34B USD.
What is Dermapharm net income for the last year?
DMPHF net income for the last year is 152.44M USD.
Does Dermapharm pay dividends?
Yes, DMPHF dividends are paid annual. The last dividend per share was 1 USD. As of today, Dividend Yield (FWD)% is 2.1%.
How many employees does Dermapharm have?
As of September 04, 2026, the company has 3,500 employees.
In which sector is Dermapharm located?
Dermapharm operates in the Health & Wellness sector.
When did Dermapharm complete a stock split?
Dermapharm has not had any recent stock splits.
Where is Dermapharm headquartered?
Dermapharm is headquartered in Grünwald, Germany.